Metraipolis › archive › dc_f1447634bf32

Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Europe PMC PMID:42830764

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42830764
DOI
10.1016/j.ajpc.2026.101719
License (as archived)
solo-consultazione
Archived
2026-10-26T20:01:57.393Z
SHA-256 of the archived text
690858c9dfc4b0a132aa4546edfb0fcbd944d8d20104866df2ec1970e791b35b
Stable URL of this page
https://metraipolis.com/documento/dc_f1447634bf32

How to cite

Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Europe PMC PMID:42830764 — Europe PMC (en), https://europepmc.org/article/MED/42830764 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f1447634bf32 (Metraipolis archive dc_f1447634bf32, sha256 690858c9dfc4b0a132aa4546edfb0fcbd944d8d20104866df2ec1970e791b35b)
BibTeX
@misc{dcf1447634bf32,
  title = {Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines — Europe PMC PMID:42830764},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42830764},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f1447634bf32; sha256 690858c9dfc4b0a132aa4546edfb0fcbd944d8d20104866df2ec1970e791b35b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42830764. Agents can read the archived copy with the MCP tool read_document.